AmVac Initiates Phase III Trial for the Treatment of Bacterial Vaginosis

19-Jun-2014 - AmVac AG announced the initiation of a Phase III study with AmVac’s lead vaccine Gynevac in Bacterial Vaginosis (BV). The trial aims to confirm the safety and efficacy of a new generation of the vaccine produced in accordance to the current GMP standards. The previous version, containing ...

AmVac AG Granted a European Patent for ProstaVac

23-Jun-2010 - European patent EP 1272216B1 with the title "Vaccine consisting of lactobacilli for the treatment of inflammation of the prostate and benign prostatic hyperplasia" was granted by the European Patent Office on9.6.2010. AmVac AG holds a licence for the above patent. Granting of the patent is a ...

AmVac AG Granted Patent for new Vaccine Development

07-Apr-2010 - AmVac AG has been granted a European patent (EP 1851 239 B1) for its Sendai platform technology for its subsidiary company AmVac Research GmbH. Thus, the novel technology for producing vaccines that has been developed at the research site in Martinsried, Germany, is completely covered by the ...

AmVac AG Begins Research Cooperation with Bayer

Research Laboratory Inaugurated in Catania

16-Jun-2008 - AmVac AG is starting its first research cooperation program with Bayer Innovation GmbH on the development of a new influenza vaccine. Joint research and development work is beginning with the Bayer subsidiary Icon Genetics GmbH on a novel production approach. Antigens are to be produced for the ...

Ascenion Mediates License Agreement on Novel Vaccine Adjuvant between HZI and AmVac

14-Dec-2007 - The Helmholtz Centre for Infection Research in Braunschweig (HZI) and AmVac AG entered into a license agreement providing AmVac with exclusive rights to develop and commercialize a synthetic lipopeptide called MALP-2 and its derivatives as vaccine adjuvants. In return, HZI receives upfront and ...